Trial Profile

Frontline Therapy of GC012F Injection in Transplant Eligible Newly Diagnosed Multiple Myeloma Patients With High-Risk Profile

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0120 (Primary) ; Bortezomib; Dexamethasone; Epirubicin; Lenalidomide
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

29 Jan 2024 According to a Gracell Biotechnology media release, the Investigational New Drug (IND) application has cleared by FDA for initiation of Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM).
12 Dec 2023 Results (As of June 9th, 2023 data cutoff, n=22 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 According to a Gracell Biotechnology media release, updated results from this trial were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com